Abstract
Multiple Myeloma has been recognized since Ancient Times. The first well-documented case was reported in 1844 by Samuel Solly. The most commonly recognized case is that of Thomas Alexander McBean, a highly respectable tradesman from London in 1850. Mr. McBean excreted a large amount of protein that was described by Henry Bence Jones in the middle of the 19th century. Jones was a well-known physician and made many contributions to medicine. One of the best known cases of multiple myeloma was that of Dr. Loos that was reported by Otto Kahler. The recognition of plasma cells and subsequently their product, a monoclonal protein has been described in detail. The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide.
MeSH terms
-
Adrenal Cortex Hormones / history
-
Adrenal Cortex Hormones / therapeutic use
-
Alkylating Agents / history
-
Alkylating Agents / therapeutic use
-
Bence Jones Protein / analysis
-
Bence Jones Protein / history
-
Boronic Acids / therapeutic use
-
Bortezomib
-
History, 19th Century
-
History, Ancient
-
Humans
-
Lenalidomide
-
Melphalan / therapeutic use
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / history*
-
Paraproteinemias / history
-
Prednisone / therapeutic use
-
Proteinuria / history
-
Pyrazines / therapeutic use
-
Stem Cell Transplantation
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Urethane / therapeutic use
Substances
-
Adrenal Cortex Hormones
-
Alkylating Agents
-
Boronic Acids
-
Pyrazines
-
Urethane
-
Thalidomide
-
Bortezomib
-
Bence Jones Protein
-
Lenalidomide
-
Melphalan
-
Prednisone